OncoMatch/Clinical Trials/NCT06708897
A Phase 1 Study of ZE50-0134 in Relapsed and Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Select Low-grad Lymphomas
Is NCT06708897 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies ZE 50-0134 for cll / sll.
Treatment: ZE 50-0134 — This is a clinical study aiming to evaluate the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of ZE50-0134 in relapsed and refractory chronic lymphocytic leukemia, small lymphocytic lymphoma, and select low-grad lymphomas.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Chronic Lymphocytic Leukemia
Non-Hodgkin Lymphoma
Biomarker criteria
Excluded: TP53 deletion
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: BTK inhibitor
have received ≥2 prior therapies that have included a BTKi
Must have received: BCL2 inhibitor (venetoclax)
have received ≥2 prior therapies that have included a BTKi and venetoclax (or declined this)
Must have received: CD20 antibody-based therapy
received at least 2 therapies including a BTKi and CD20 antibody-based therapy
Cannot have received: BCL2 inhibitor (venetoclax)
No prior venetoclax treatment (FOR PART 2 ONLY)
Lab requirements
Blood counts
ANC > 0.75 x 10^9/L (or ≥ 0.5 x 10^9/L with bone marrow involvement); Platelet count > 50 x 10^9/L (or ≥ 30 x 10^9/L with bone marrow involvement)
Kidney function
Creatinine or Cystatin C GFR ≥60 mL/min
Liver function
AST/SGOT or ALT/SGPT ≤ 3.0 x ULN; Total bilirubin ≤ 1.5 x ULN
Adequate bone marrow, liver, and renal functions as assessed by the following laboratory requirements
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Norton Cancer Institute, St. Matthews Campus · Louisville, Kentucky
- University of North Carolina at Chapel Hill · Chapel Hill, North Carolina
- University of Cincinnati · Cincinnati, Ohio
- The Ohio State University · Columbus, Ohio
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06708897 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior BCL2 inhibitor disqualifies patients from enrollment.
Are patients with TP53 alterations eligible?
No. TP53 deletion is an exclusion criterion.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify